Brevan Howard Capital Management LP Buys 846,070 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Brevan Howard Capital Management LP lifted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 2,795.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 876,340 shares of the company's stock after purchasing an additional 846,070 shares during the quarter. Brevan Howard Capital Management LP owned 0.70% of Humacyte worth $4,426,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Barclays PLC increased its stake in shares of Humacyte by 177.6% in the 3rd quarter. Barclays PLC now owns 236,742 shares of the company's stock valued at $1,288,000 after purchasing an additional 151,458 shares during the last quarter. Brookstone Capital Management bought a new stake in shares of Humacyte during the 4th quarter valued at about $56,000. Clarus Wealth Advisors bought a new stake in shares of Humacyte in the 4th quarter valued at $207,000. ARS Investment Partners LLC increased its position in Humacyte by 17.8% in the 4th quarter. ARS Investment Partners LLC now owns 99,419 shares of the company's stock valued at $502,000 after buying an additional 15,000 shares in the last quarter. Finally, ACT Wealth Management LLC bought a new stake in Humacyte during the 4th quarter valued at $57,000. Institutional investors own 44.71% of the company's stock.

Humacyte Price Performance

Shares of Humacyte stock traded down $0.02 during trading hours on Friday, reaching $1.19. The company had a trading volume of 2,020,672 shares, compared to its average volume of 3,649,221. Humacyte, Inc. has a one year low of $1.15 and a one year high of $9.97. The firm has a market cap of $184.59 million, a PE ratio of -0.89 and a beta of 1.64. The business has a fifty day simple moving average of $1.95 and a 200 day simple moving average of $3.61.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.07. The firm had revenue of $7.23 million during the quarter, compared to analysts' expectations of $0.64 million. On average, research analysts forecast that Humacyte, Inc. will post -1.27 EPS for the current year.

Insider Transactions at Humacyte

In related news, Director Kathleen Sebelius acquired 50,000 shares of Humacyte stock in a transaction on Tuesday, April 8th. The shares were acquired at an average cost of $1.32 per share, with a total value of $66,000.00. Following the transaction, the director now owns 91,207 shares in the company, valued at $120,393.24. This trade represents a 121.34 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Dale A. Sander bought 20,000 shares of the stock in a transaction dated Thursday, April 10th. The stock was purchased at an average price of $1.53 per share, with a total value of $30,600.00. Following the purchase, the chief financial officer now owns 40,600 shares in the company, valued at $62,118. This trade represents a 97.09 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 83,993 shares of company stock valued at $118,224 in the last quarter. Insiders own 11.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HUMA. HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. Benchmark restated a "buy" rating on shares of Humacyte in a report on Thursday, February 27th. Finally, D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of Humacyte in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $13.71.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.